In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

The investor, who declined to be identified, pointed to Astra’s steadier flow of new products ... a former chief immunology ...

since its high degree of diversification across platforms offsets the variable outcomes for drug development and competitive challenges to the firm's leading products. Our rating for GSK is not ...

GSK plc and Chimagen Biosciences (Chimagen), a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE ...

The five-year partnership, which builds on their existing scientific partnership, will be known as the Cambridge-GSK Translational Immunology Collaboration. Its focus will be on refining the ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

Sosei Group Corporation has initiated discussions to regain full ownership of the oral inflammatory bowel disease (IBD) drug GSK4381406 from GSK. Sosei Heptares plans to regain ownership of ...

GSK, formerly known as GlaxoSmithKline, continues to distinguish itself through its vast array of medicines, vaccines and consumer health care products ... in oncology, immunology and ...

GlaxoSmithKline ( (GSK) ) has realeased its Q3 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.

GSK is delivering consistent financial performance ... which Deborah will cover shortly. Respiratory and immunology products were up 14%, and Nucala IL5 biologic treatment was up 12%.